Search Results - "Vynnychenko, O."

Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology by Vynnychenko, O., Moskalenko, R.

“…In 2022, 2.3 million new cases of breast cancer were registered in the world, which accounted for 11.6% of the total number of malignant neoplasms. Depending…”
Get full text

The role of PIK3CA mutations in the development of breast cancer (a literature review) by Pryvalova, A. O., Vynnychenko, I. O., Harbuzova, V. Yu, Vynnychenko, O. I., Moskalenko, Yu. V.

“…Today, breast cancer occupies a leading position in the structure of morbidity and mortality among women in Ukraineand and throughout the world. Late diagnosis…”
Get full text

Modern vector in treatment of patients with lung cancer: tyrosine kinase inhibitors in epidermal growth factor receptor mutations (literature review) by Smorodska, O.M., Moskalenko, Yu.V., Vynnychenko, I.O., Vynnychenko, O.I., Kostuchenko, V.V.

“…Tumor molecular profiling in patients with non-small cell lung cancer (NSCLC) is used to identify driver mutations, which lead to premature carcinogenesis in…”
Get full text

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC) by Wakelee, Heather A., Altorki, Nasser K., Zhou, Caicun, Csőszi, Tibor, Vynnychenko, Ihor O., Goloborodko, Oleksandr, Luft, Alexander, Akopov, Andrey, Martinez-Marti, Alex, Kenmotsu, Hirotsugu, Chen, Yuh-Min, Chella, Antonio, Sugawara, Shunichi, Gitlitz, Barbara J., Bennett, Elizabeth, Wu, Fan, Yi, Jing, Deng, Yu, McCleland, Mark, Felip, Enriqueta

“…Abstract only 8500 Background: Adjuvant platinum-based chemotherapy (chemo) provides only a modest 5-year survival benefit in fully resected, high-risk…”
Get full text

ANALYSIS OF THE INCIDENCE RATE OF COLORECTAL CANCER AMONG RESIDENTS OF THE SUMY REGION by Kostiuchenko, V.V., Moskalenko, Y.V., Tarasenko, S.V., Vynnychenko, O.I., Shevchenko, V.V., Vynnychenko, I.O.

“…Before the middle of the 20th century, colorectal cancer (CRC) was a fairly rare disease. A significant increase in the prevalence of this pathology began…”
Get full text

Preliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study by Bondarenko, I., Juan-Vidal, O., Pajkos, G., Kryzhanivska, A., Pápai Székely, Z., Vicente, D., Vynnychenko, I.O., Jones, S., Wang, Y., Jiang, H., Reinmuth, N.

Get full text

Вплив внутрішньочеревного тиску на газообмін і механіку дихання у пацієнтів з морбідним ожирінням під час проведення штучної вентиляції легенів by Mazur, A. P., Vynnychenko, O. V.

“…Мета. Покращити результати штучної вентиляції легенів у пацієнтів з морбідним ожирінням. Матеріали і методи. До даного дослідження залучено 81 хворого, якому…”
Get full text

The problem of the female priesthood in foreign Protestantism by O. Vynnychenko-Boruh

“…One of the tendencies of modern transformations in the religious sphere, in particular in the world of Protestantism, is the desire for gender equality. The…”
Get full text

Next-generation sequencing is a prerequisite for personalized lung cancer treatment by Vynnychenko, O. I., Moskalenko, R. A., Kozakov, D. S., Livshun, S. S., Sulaieva, O. M.

Get full text

P-195 PREVENTION OF EARLY GASTRIC EMPTYING AND LATE DUODENO-GASTRO-OESOPHAGEAL REFLUX AFTER OESOPHAGOGASTROSTOMY: IS THERE ONE SOLUTION? by Vynnychenko, O., Vynnychenko, I.

Get full text

Surgical treatment of diabetes mellitus type II associated with morbid obesity by Todurov, I M, Bilians'kyĭ, L S, Perekhrestenko, O V, Kalashnikov, O O, Davydenko, N H, Vynnychenko, O V

Get full text

Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426 by Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dmitry, Pouliot, Frederic, Alekseev, Boris, Soulieres, Denis, Melichar, Bohuslav, Vynnychenko, Ihor O., Azevedo, Sergio Jobim, Borchiellini, Delphine, McDermott, Raymond S., Bedke, Jens, Tamada, Satoshi, Wu, Sterling, Burgents, Joseph, Molife, L. Rhoda, Powles, Thomas

“…LBA4501 Background: At the first interim analysis of the randomized, open-label, phase 3 KEYNOTE-426 (NCT02853331) study, 1L pembro + axi showed statistically…”
Get full text

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426 by Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Waddell, Tom, Gafanov, Rustem, Pouliot, Frédéric, Nosov, Dmitry, Melichar, Bohuslav, Soulieres, Denis, Borchiellini, Delphine, Vynnychenko, Ihor O., McDermott, Raymond S., Azevedo, Sergio Jobim, Tamada, Satoshi, Kryzhanivska, Anna, Li, Chenxiang, Burgents, Joseph E., Molife, L. Rhoda, Bedke, Jens, Powles, Thomas

“…Abstract only 4500 Background: In the first interim analysis of the randomized, multicenter, open-label, phase 3 KEYNOTE-426 study (NCT02853331), treatment…”
Get full text

1665PDPreliminary efficacy of durvalumab plus tremelimumab in platinum-refractory/resistant ED-SCLC from arm A of the phase II BALTIC study by Bondarenko, I, Juan-Vidal, O, Pajkos, G, Kryzhanivska, A, Pápai Székely, Z, Vicente, D, Vynnychenko, I O, Jones, S, Wang, Y, Jiang, H, Reinmuth, N

Get full text